Zobrazeno 1 - 10
of 220
pro vyhledávání: '"J. Fradette"'
Autor:
Jessica M. Konen, B. Leticia Rodriguez, Haoyi Wu, Jared J. Fradette, Laura Gibson, Lixia Diao, Jing Wang, Stephanie Schmidt, Ignacio I. Wistuba, Jianjun Zhang, Don L. Gibbons
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 17 (2023)
Non–small cell lung cancers that harbor concurrent KRAS and TP53 (KP) mutations are immunologically warm tumors with partial responsiveness to anti–PD-(L)1 blockade; however, most patients observe little or no durable clinical benefit. To identif
Externí odkaz:
https://doaj.org/article/c91ebec70cb74fa7b67c8100444ae89e
Autor:
B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica M. Konen, Frank R. Rojas Alvarez, Luisa M. Solis, Xiaohui Yi, Aparna Padhye, Laura A. Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don L. Gibbons
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionDespite significant clinical advancement with the use of immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) there are still a major subset of patients that develop adaptive/acquired resistance. Understanding resistance
Externí odkaz:
https://doaj.org/article/b7f1eb8f62594da3a8e2703ca0fd91c7
Autor:
David H. Peng, B. Leticia Rodriguez, Lixia Diao, Pierre-Olivier Gaudreau, Aparna Padhye, Jessica M. Konen, Joshua K. Ochieng, Caleb A. Class, Jared J. Fradette, Laura Gibson, Limo Chen, Jing Wang, Lauren A. Byers, Don. L. Gibbons
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Recent clinical trials combining MEK inhibitors with anti-PD-L1 in solid tumours show moderate responses. Here, the authors demonstrate that the combination of MEK inhibition and PD-L1 blockade in KRAS mutant lung cancer models leads to a transient t
Externí odkaz:
https://doaj.org/article/c550e9da14dd40faac0c52202ab9def2
Autor:
Aparna Padhye, Jessica M. Konen, B. Leticia Rodriguez, Jared J. Fradette, Joshua K. Ochieng, Lixia Diao, Jing Wang, Wei Lu, Luisa S. Solis, Harsh Batra, Maria G. Raso, Michael D. Peoples, Rosalba Minelli, Alessandro Carugo, Christopher A. Bristow, Don L. Gibbons
Publikováno v:
JCI Insight, Vol 6, Iss 17 (2021)
Lack of sustained response to therapeutic agents in patients with KRAS-mutant lung cancer poses a major challenge and arises partly due to intratumor heterogeneity that defines phenotypically distinct tumor subpopulations. To attain better therapeuti
Externí odkaz:
https://doaj.org/article/68b2c3b3409d42f9a4a84381305fc816
Autor:
Roxsan Manshouri, Etienne Coyaud, Samrat T. Kundu, David H. Peng, Sabrina A. Stratton, Kendra Alton, Rakhee Bajaj, Jared J. Fradette, Rosalba Minelli, Michael D. Peoples, Alessandro Carugo, Fengju Chen, Christopher Bristow, Jeffrey J. Kovacs, Michelle C. Barton, Tim Heffernan, Chad J. Creighton, Brian Raught, Don L. Gibbons
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Non-small cell lung cancer (NSCLC) is often associated with metastasis to the lungs. Here, the authors perform independent screens and identify NuRD as a co-repressor of ZEB1, and demonstrate TBC1D2b as a downstream target of ZEB1/NuRD complex regula
Externí odkaz:
https://doaj.org/article/175dfc318ac14591a1188315ed141a14
Autor:
Mabel Perez-Oquendo, Roxsan Manshouri, Yanhua Tian, Jared J. Fradette, B. Leticia Rodriguez, Samrat T. Kundu, Don L. Gibbons
Publikováno v:
Molecular Cancer Research. :OF1-OF16
Epithelial-to-mesenchymal transition results in loss of specialized epithelial cell contacts and acquisition of mesenchymal invasive capacity. The transcription repressor zinc finger E-box-binding homeobox 1 (ZEB1) binds to E-boxes of gene promoter r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef9fd47ed40eeb3e8b97b12af14c07ab
https://doi.org/10.1158/1541-7786.mcr-22-0503
https://doi.org/10.1158/1541-7786.mcr-22-0503
Autor:
Samrat T. Kundu, Caitlin L. Grzeskowiak, Jared J. Fradette, Laura A. Gibson, Leticia B. Rodriguez, Chad J. Creighton, Kenneth L. Scott, Don L. Gibbons
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-16 (2018)
One of the major causes of cancer-related mortality is represented by metastatic lung cancer. Here the authors characterize the role of TMEM106B in driving metastatic lung adenocarcinoma and suggest that TMEM106B-mediated secretion of cathespin impac
Externí odkaz:
https://doaj.org/article/3eec8884c2534e3ab8b673a78e5f82ba
Autor:
Caitlin L. Grzeskowiak, Samrat T. Kundu, Xiulei Mo, Andrei A. Ivanov, Oksana Zagorodna, Hengyu Lu, Richard H. Chapple, Yiu Huen Tsang, Daniela Moreno, Maribel Mosqueda, Karina Eterovic, Jared J. Fradette, Sumreen Ahmad, Fengju Chen, Zechen Chong, Ken Chen, Chad J. Creighton, Haian Fu, Gordon B. Mills, Don L. Gibbons, Kenneth L. Scott
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
KRAS-driven lung cancers represent an aggressive form of NSCLC. In this study the authors perform an in vivo functional screening and identify GATAD2B as a driver of tumor growth and metastasis in KRAS-driven lung cancer.
Externí odkaz:
https://doaj.org/article/7d3a32362fb643e9a451c28f602e01e5
Autor:
Don L. Gibbons, Samrat T. Kundu, B. Leticia Rodriguez, Jared J. Fradette, Yanhua Tian, Roxsan Manshouri, Mabel Perez-Oquendo
Potential ZEB1 acetylation-dependent target genes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eeab979685dc8add788223bcc2e7dde
https://doi.org/10.1158/1541-7786.23268831.v1
https://doi.org/10.1158/1541-7786.23268831.v1
Autor:
Don L. Gibbons, Samrat T. Kundu, B. Leticia Rodriguez, Jared J. Fradette, Yanhua Tian, Roxsan Manshouri, Mabel Perez-Oquendo
qPCR Primer Sequences
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::296ce98742943908e66791ec14b74a9b
https://doi.org/10.1158/1541-7786.23268825
https://doi.org/10.1158/1541-7786.23268825